With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to ...

The article " Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns " first appeared on MarketBeat.

According to Report Ocean, the US Urinary Tract Infection (UTI) Therapeutics market is anticipated to grow at a CAGR of ~$% between 2022-2028 owing to rise in cases of UTIs, technological advancements ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

Cambridge: Atavistik Bio, a biotechnology company has announced that it has entered into a research collaboration with Pfizer ...

Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and ...

Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...

and Braftovi brands Sterile injectable and anti-infective medicines and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. Pfizer also ...

The FDA had approved Tagrisso for a similar use in September. FDA Approves Pfizer’s Braftovi for First-Line Colorectal Cancer The FDA approved Pfizer’s Braftovi in combination with Erbitux ...

NEW YORK, December 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ...